Results 1 to 10 of about 52,225 (202)

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha [PDF]

Journal of Hematology & Oncology, 2019
Background Interferon alpha (IFNa) monotherapy is recommended as the standard therapy in polycythemia vera (PV) but not in chronic myeloid leukemia (CML). Here, we investigated the mechanisms of IFNa efficacy in JAK2V617F- vs.
Claudia Schubert, Manuel Allhoff, Stefan Tillmann, Tiago Maié, Ivan G. Costa, Daniel B. Lipka, Mirle Schemionek, Kristina Feldberg, Julian Baumeister, Tim H. Brümmendorf, Nicolas Chatain, Steffen Koschmieder   +11 more
doaj   +3 more sources

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells [PDF]

Scientific Reports, 2022
In this study, we examined the antileukemic effects of pterostilbene, a natural methylated polyphenol analog of resveratrol that is predominantly found in berries and nuts, using various human and murine leukemic cells, as well as bone marrow samples ...
Shohei Kawakami, Mitsuyo Tsuma-Kaneko, Masakazu Sawanobori, Tomoko Uno, Yoshihiko Nakamura, Hideyuki Matsuzawa, Rikio Suzuki, Makoto Onizuka, Takashi Yahata, Kazuhito Naka, Kiyoshi Ando, Hiroshi Kawada   +11 more
doaj   +5 more sources

EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway. [PDF]

Oncol Rep, 2018
Although the introduction of tyrosine kinase inhibitors greatly improved the survival of patients with chronic myeloid leukemia (CML), drug resistance remains a problem. Thus, mechanism-based novel therapeutic targets warrant exploration. Recently, epidermal growth factor receptor kinase substrate 8 (EPS8), which has been identified as an oncogene and ...
Huang R, Liu H, Chen Y, He Y, Kang Q, Tu S, He Y, Zhou X, Wang L, Yang J, Wu A, Li Y.   +11 more
europepmc   +5 more sources

Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. [PDF]

Haematologica, 2015
Philadelphia chromosome (Ph)/BCR/ABL-positive acute lymphoblastic leukemia (ALL) is the most common genetic abnormality associated with adult ALL and has been shown to confer the worst prognosis to both children and adults.[1][1],[2][2] Approximately 3%–5% children and 25%–40% adults with ...
Leoni V, Biondi A.
europepmc   +6 more sources

BCR/ABL positive thrombocythemia: a diagnostic dilemma

The Egyptian Journal of Internal Medicine, 2017
Both chronic myeloid leukemia and essential thrombocythemia are part of the spectrum of myeloproliferative neoplasm. Therefore, considerable overlap may occur in the clinical manifestations, and hematological and molecular findings in some patients.
Lubna Zafar, Feroz Alam, Anjum Parvez, Srikant Behera   +3 more
doaj   +3 more sources

Case report: BCR-ABL-positive acute lymphoblastic leukemia with bone destruction: a treatment dilemma [PDF]

Frontiers in Oncology
Although bone destruction and hypercalcemia without acute peripheral blast BCR-ABL-positive acute lymphoblastic leukemia (ALL) have been reported in children, they are rare in adults.
Shi Lijun, Ma Zhongrui, Ma Zhongrui, Wei Li, Yu Xia, Jiang Wei, Pan Yaning   +6 more
doaj   +2 more sources

Retraction Note: Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. [PDF]

Leukemia, 2020
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Wu LX, Xu JH, Zhang KZ, Lin Q, Huang XW, Wen CX, Chen YZ.   +6 more
europepmc   +4 more sources

Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias [PDF]

Advances in Hematology, 2015
BCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia (ALL), are the paradigm of targeted molecular therapy of cancer due to the impressive clinical responses obtained with BCR-ABL ...
Alessandro Morotti, Giovanna Carrà, Cristina Panuzzo, Sabrina Crivellaro, Riccardo Taulli, Angelo Guerrasio, Giuseppe Saglio   +6 more
doaj   +3 more sources

Durable MRD-Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. [PDF]

EJHaem
ABSTRACT Introduction Tyrosine kinase inhibitors (TKIs) are standard therapy for Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL); however, relapsed or refractory disease remains challenging due to resistance driven by ABL kinase domain mutations.
Qadir MS, Farooq S, Jamy O.
europepmc   +2 more sources

Multi-Lineage BCR-ABL Expression in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Associated With Improved Prognosis but No Specific Molecular Features

Frontiers in Oncology, 2020
BackgroundRecently, various blood cell lineages expressing the BCR-ABL fusion gene in Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have been reported. However, the biological and clinical significance of these BCR-ABL lineages
Satoshi Nishiwaki, Jeong Hui Kim, Masafumi Ito, Matsuyoshi Maeda, Yusuke Okuno, Daisuke Koyama, Yukiyasu Ozawa, Masaharu Gunji, Masahide Osaki, Kunio Kitamura, Yoko Ushijima, Yuichi Ishikawa, Koichi Miyamura, Isamu Sugiura, Hitoshi Kiyoi   +14 more
doaj   +3 more sources